Richardson-Heron Dara 4

What Happened

• Dara Richardson-Heron, a director of Caribou Biosciences, was granted an award of 45,000 derivative securities on February 20, 2026. The reported price is $0.00 per share (the filing lists the grant as a derivative award, not an open-market purchase or sale).

Key Details

• Transaction date: 2026-02-20
• Transaction type/code: Award/Grant (A) — derivative security
• Shares/units granted: 45,000 at $0.00 per share (total reported value $0 in the filing)
• Vesting: One-twelfth of the award vests each monthly anniversary of the grant date; fully vested on February 20, 2027, subject to continued service (see footnote)
• Shares owned after transaction: Not specified in the Form 4 filing
• Timeliness: Reported on the same date (filing period 2026-02-20); no late filing indicated

Context

• This was a compensation-related award (derivative grant) to a director, not an open-market purchase or sale. Because the award vests monthly over one year, the recipient does not receive fully vested, transferable shares immediately. Such grants are common for board compensation and do not by themselves indicate buying or selling sentiment.